Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Janux Therapeutics’ $193.8 Million IPO
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
Janux Therapeutics’ $125 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal while Morrison & Foerster LLP represented RA Capital and OrbiMed as lead investors. Janux Therapeutics...
Janux Therapeutics’ $56 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal. Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T...